# Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

> **NCT00932698** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Relapsed and Refractory Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib

## Key facts

- **NCT ID:** NCT00932698
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-12
- **Primary completion:** 2013-06-20
- **Final completion:** 2017-05-23
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932698, "Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00932698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*